Endstage Renal Disease Clinical Trial
Official title:
The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects With End-Stage Renal Disease Treated With Haemodialysis - A Randomised Clinical Trial
The purpose of this trial is to examine the effect of increasing dialyse magnesium on serum calcification propensity in subjects with end-stage renal disease treated with haemodialysis.
Patients with end-stage renal disease (ESRD) have a 20-fold increased risk of cardiovascular
mortality compared to the general population. Arterial stiffness, likely due to vascular
calcification (VC), has been shown to predict cardiovascular mortality in ESRD. Serum
calcification propensity (T50) is a novel biomarker, which is believed to reflect the
propensity toward ectopic calcification (e.g. VC). Increasing serum magnesium (sMg) should
increase T50, which might in turn reduce the formation of VC in patients with ESRD. A cheap
and easy way of achieving this would be to increase the concentration of Mg in the dialysate
(dMg) of patients with ESRD treated with haemodialysis (HD).
The investigators wish to conduct a randomised controlled double-blind clinical trial to
examine whether increasing dMg will improve T50 in subjects with ESRD treated with HD.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03023748 -
Intravenous Paricalcitol in Chronic Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT00745914 -
Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients
|
N/A | |
Terminated |
NCT00776191 -
Randomized Multicenter Cross-over Study to Compare the Effect of Physioneal 35 to 40 on the Protein Metabolism
|
Phase 4 | |
Completed |
NCT02981706 -
Comparison of AVF Versus AVG in Elderly Patients Starting Dialysis
|
N/A | |
Completed |
NCT02946229 -
Data Collection for Next Generation Ultrasound Technology Development
|
N/A | |
Completed |
NCT02966028 -
Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
|
Phase 2 | |
Completed |
NCT02976246 -
Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients
|
Phase 4 | |
Recruiting |
NCT02957877 -
LMWH Infusion as Anticoagulation for Home HD
|
Phase 4 | |
Completed |
NCT00745719 -
Parathyroidectomy in Endstage Renal Disease
|
N/A | |
Completed |
NCT03010072 -
The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum
|
Phase 2 | |
Recruiting |
NCT03020303 -
Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease
|
Phase 3 | |
Completed |
NCT00745589 -
Sevelamer Hydrochloride in Peritoneal Dialysis Patients
|
N/A | |
Not yet recruiting |
NCT02976688 -
Effects of Short-chain Fatty Acids on Inflammatory and Metabolic Parameters in Maintenance Hemodialysis
|
Phase 2/Phase 3 | |
Completed |
NCT02970201 -
Improving Adherence in Renal Dialysis Patients Through Electronic Interventions
|
N/A | |
Withdrawn |
NCT00502268 -
Vitamin D and Carboxy PTH Fragments in Coronary Calcification
|
Phase 4 | |
Completed |
NCT02207153 -
Risk Assessment by Cardiovascular Biomarkers in Chronic Dialysis Patients
|
||
Completed |
NCT02866214 -
Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT03054454 -
A Podiatry Led MDT Intervention to Reduce the Burden of Foot Disease in Patients With End Stage Kidney Failure
|
N/A |